Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
2Debt Items
10Related Chains
Source-Backed Evidence Depth
Avenue Therapeutics, Inc. (ATXI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
3Distinct source URLs
4High confidence
0.782Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Avenue Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
DUKE-UNIVERSITY
DUKE-UNIVERSITY
92%
Under the License Agreement, the Company agreed to make an upfront payment and reimburse certain patent expenses to Duke
Reciprocal relationship from FBIO graph: Zeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“Sentynl”), Axsome Therapeutics, Inc. (“Axso…
Avenue Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ANNJI
ANNJI
92%
Under the Termination and Transfer Agreement, AnnJi agreed to pay the Company $ 1.6 million (net of withholding taxes), which was received in 2025.
Reciprocal relationship from FBIOP graph: Reciprocal relationship from ATXI graph: product candidates and will rely on third parties to manufacture any products for which we receive regulatory approv…
product candidates and will rely on third parties to manufacture any products for which we receive regulatory approval and their failure to produce them in the volumes that we require on a timely bas…
ANNJI-PHARMACEUTICAL-CO-LTD
ANNJI-PHARMACEUTICAL-CO-LTD
62%
not material for the three months ended March 31, 2026 and 2025 . Summary of Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies to th…
CO-LLC
CO-LLC
62%
rs, and smaller reporting companies are permitted to delay adoption of certain recent accounting. Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements…
Avenue Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ATXI-DEBT-7963
Warrants outstanding: 545454
90%
xbrl warrant detail from xbrl 2026-03-31.
ATXI-DEBT-7964
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
Avenue Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Avenue Therapeutics, Inc..
Avenue Therapeutics, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Avenue Therapeutics, Inc..
Avenue Therapeutics, Inc. Extended Supply Chain Network
